Blog
Performance-based pricing, part 2
A few more thoughts on drug pricing, following up on a prior post.
Performance-based drug pricing and the "Wanamaker problem"
We have tools available today to improve the drug pricing system. Let's start using them.
Oncology combinations – four key elements to biopharma success
If Pharma companies want to succeed in cancer R&D, they need to get better at handling combinations. Here are some places to start.